Press release summary
BASEL, Switzerland โ Roche said Nov. 16 that the U.S. Food and Drug Administration granted De Novo authorization for the cobas pro i 601 platform with the Ionify Gabapentin assay, components of the companyโs automated clinical mass spectrometry system.
The assay adds therapeutic drug monitoring for gabapentin to a U.S. menu that includes total 25-hydroxy vitamin D and steroid hormone tests. Roche designed the system to integrate mass spectrometry into a standardized core-laboratory workflow, including automated sample preparation, analysis and result processing.
The authorization also includes a predetermined change control plan. Roche said the plan could support the addition of as many as 22 Ionify assays when specified FDA requirements are met. Those assays are not yet available, and each future addition remains subject to the authorized planโs conditions.
Why it matters: Clinical mass spectrometry often requires specialized staff and labor-intensive preparation. An authorized automated platform could help more routine laboratories adopt the technology for therapeutic drug monitoring while improving standardization. Laboratories evaluating the system should still review assay-specific performance, staffing, interfaces, quality control, maintenance and local regulatory status.









Leave a Reply